SOT Stock Overview
A pharmaceutical company, engages in the manufacturing and sale of medicines in Morocco. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for SOT from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Société de Therapeutique Marocaine S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.م948.00 |
| 52 Week High | د.م1,065.00 |
| 52 Week Low | د.م881.00 |
| Beta | -0.13 |
| 1 Month Change | 1.91% |
| 3 Month Change | -5.29% |
| 1 Year Change | -11.32% |
| 3 Year Change | -36.08% |
| 5 Year Change | 133.93% |
| Change since IPO | 611.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOT | MA Pharmaceuticals | MA Market | |
|---|---|---|---|
| 7D | 2.9% | 1.8% | -0.1% |
| 1Y | -11.3% | -7.3% | 18.2% |
Return vs Industry: SOT underperformed the MA Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: SOT underperformed the MA Market which returned 18.2% over the past year.
Price Volatility
| SOT volatility | |
|---|---|
| SOT Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in MA Market | 7.4% |
| 10% least volatile stocks in MA Market | 2.1% |
Stable Share Price: SOT has not had significant price volatility in the past 3 months compared to the MA market.
Volatility Over Time: SOT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,179 | Lamia Tazi | www.sothema.com |
Société de Therapeutique Marocaine S.A., a pharmaceutical company, engages in the manufacturing and sale of medicines in Morocco. It offers products in various therapeutic areas, including allergology, oncology, cardiology, dental, dermatology, endocrinology, gastroenterology, gynecology, ophthalmology, ENT, pediatric, pulmonology, reanimation, rheumatology, central nervous system (CNS), and urology, as well as antibiotics and other generic drugs. The company also provides its products in various forms, such as tablets, capsules, pouches, syrups, suspensions, powders, collyriums, suppositories, creams and pomades, injectable solutions, and self-injectable syringes.
Société de Therapeutique Marocaine S.A. Fundamentals Summary
| SOT fundamental statistics | |
|---|---|
| Market cap | د.م6.83b |
| Earnings (TTM) | د.م280.52m |
| Revenue (TTM) | د.م2.63b |
24.3x
P/E Ratio2.6x
P/S RatioIs SOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOT income statement (TTM) | |
|---|---|
| Revenue | د.م2.63b |
| Cost of Revenue | د.م1.44b |
| Gross Profit | د.م1.19b |
| Other Expenses | د.م907.91m |
| Earnings | د.م280.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 38.96 |
| Gross Margin | 45.19% |
| Net Profit Margin | 10.67% |
| Debt/Equity Ratio | 38.5% |
How did SOT perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield44%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:57 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Société de Therapeutique Marocaine S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hicham Saadani | Bmce Capital Bourse |
| null null | Upline Securities |